微芯生物(688321.SH):西奧羅尼膠囊納入擬突破性治療品種公示
格隆匯3月16日丨微芯生物(688321.SH)公佈,公司產品西奧羅尼膠囊近日被國家藥品監督管理局藥品審評中心納入擬突破性治療品種公示名單,公示期7日(2021年3月16日-2021年3月23日)。
西奧羅尼,是公司自主研發的機制新穎的靶向三通路選擇性激酶抑制劑,屬於小分子抗腫瘤原創新藥,它針對主要幾種腫瘤相關靶標蛋白激酶AuroraB、VEGFR1,2,3、PDGFRα/β、和CSF-1R均有顯著的體外抑制活性(IC50小於10nM)。通過抑制細胞週期調控激酶AuroraB,西奧羅尼可以抑制腫瘤細胞的週期進程,降低腫瘤的增殖活性;通過抑制與血管生成相關的VEGFR和PDGFR,西奧羅尼可以抑制腫瘤的新生血管形成,從而減少腫瘤的血液供應和生長;通過抑制與免疫細胞增殖活化相關的CSF1R,西奧羅尼可以抑制腫瘤局部免疫抑制性細胞的生長,從而提高機體對腫瘤的免疫監測和免疫清除功能。綜合而言,西奧羅尼通過上述抑制腫瘤細胞有絲分裂、抑制腫瘤血管生成和調節腫瘤免疫微環境的三種活性機制,發揮綜合抗腫瘤作用。目前,西奧羅尼正在開展小細胞肺癌、卵巢癌、肝癌、乳腺癌、淋巴瘤、其他神經內分泌腫瘤等多個適應症的不同階段研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.